TGF?NanoCap is an oral combination of nanoparticulate transforming growth factor beta 1 (TGF?) and all- trans retinoic acid (ATRA) in pre-clinical development for treatment of inflammatory bowel disease (IBD). Phase I studies provided proof-of-principle for efficacy in a murine model. Phase II work optimized therapeutic protocol, confirmed efficacy in a second model, established scale-up manufacturing methods, completed rodent toxicology studies, and conducted a type C meeting with the FDA to gain guidance in support of an investigational new drug (IND) filing. The present application (according to FDA guidance) proposes additional rodent toxicology and formulation studies, synthesis and qualification of drug product for use in non-human primates, execution of a type B pre-IND meeting with the FDA and finally, required primate toxicology in support of an open IND application. Work will be performed in collaboration with Bend Research, Inc., Comparative Biosciences Inc. and Regulatory Professionals Inc., as well as with Dr. Peter Mannon, Professor of Medicine, Division of Gastroenterology & Hepatology, and Director Gastroenterology/Hepatology Clinical Research Program at the University of Alabama. Successful completion of the Phase IIb studies will facilitate the advancement of TGF?NanoCap towards phase I/II clinical trials in patients with Crohn?s disease and ulcerative colitis.

Public Health Relevance

Current therapies for inflammatory bowel diseases (IBD) such as Crohn?s disease and ulcerative colitis fail a considerable percentage of patients due to ineffectiveness or therapy-limiting side effects. TherapyXInc is developing a more advanced drug delivery system that targets Transforming Growth Factor ?-1 and Retinoic Acid to the site of inflammation in the gut thereby reducing systemic side effects. This therapy has the potential to significantly improve morbidity and quality of life for those suffering with IBD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI080009-05A1
Application #
9393283
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Minnicozzi, Michael
Project Start
2008-07-20
Project End
2020-05-31
Budget Start
2017-06-20
Budget End
2018-05-31
Support Year
5
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Therapyx, Inc.
Department
Type
DUNS #
145056607
City
Buffalo
State
NY
Country
United States
Zip Code
14214